Why the study?
Does Nicorandil reduce cardiac enzyme release and improve prognosis in unstable angina patients undergoing PCI?
Does Nicorandil reduce cardiac enzyme release and improve prognosis in unstable angina patients undergoing PCI?
Peri-procedural administration of Nicorandil in unstable angina patients undergoing PCI reduces early cardiac enzyme release but does not significantly improve four-month clinical outcomes.
Introduction: Ischemic preconditioning mediated by potassium channels is a physiological protective mechanism, . It is hypothesized that Nicorandil, which is a potassium channel activator, could protect the heart via preconditioning. Materials and Methods:This clinical trial was conducted on 162 patients undergoing percutaneous coronary intervention (PCI) in Quem hospital, from Jan2013 to Jan 2014,patients divided into two groups. The first group received standard treatment plus Nicorandil (10 mg, twice daily) for three days before and after angioplasty. The second group received standard treatment after PCI. Results: Cardiac enzyme levels were significantly lower in the Nicorandil group at 6 and 12 hours after angioplasty,(p value=0.001) while no significant differences were observed in the symptoms and four-month prognosis of the study groups(p value=0.8). Conclusion:It is recommended that a randomized clinical trial be conducted for the close evaluation of the effects of Nicorandil on unstable angina patients.
No takes yet. Share an insight, caveat, or question.
Falsoleiman et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: